Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Anti-VEGF antibody bevacizumab has prolonged progression-free survival in several cancer types, however acquired resistance is common. Adaption has been observed pre-clinically, but no human study has shown timing and genes involved, enabling formulation of new clinical paradigms. In a window-of-opportunity study in 35 ductal breast cancer patients for 2weeks prior to neoadjuvant chemotherapy, we monitored bevacizumab response by Dynamic Contrast-Enhanced Magnetic Resonance [DCE-MRI], transcriptomic and pathology. Initial treatment response showed significant overall decrease in DCE-MRI median K(trans), angiogenic factors such ESM1 and FLT1, and proliferation. However, it also revealed great heterogeneity, spanning from downregulation of blood vessel density and central necrosis to continued growth with new vasculature. Crucially, significantly upregulated pathways leading to resistance included glycolysis and pH adaptation, PI3K-Akt and immune checkpoint signaling, for which inhibitors exist, making a strong case to investigate such combinations. These findings support that anti-angiogenesis trials should incorporate initial enrichment of patients with high K(trans), and a range of targeted therapeutic options to meet potential early resistance pathways. Multi-arm adaptive trials are ongoing using molecular markers for targeted agents, but our results suggest this needs to be further modified by much earlier adaptation when using drugs affecting the tumor microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166 · cited 2×
“Recently, ProgrammedDeath Ligand 1, PD-L1, not showing significant changes in this study but member of the same CD28/ CTLA4 family of receptors, has been shown to be direct target of HIF1A, and when blocked under hypoxia it enhanced myeloid-derived suppressor cells-mediated T-cell activation (Noman et al., 2014).”
BackgroundCTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685 · cited 4×
“Key immune response pathways were induced (Tables S3–S5), including CD28 and its activating binding ligand CD86.”
BackgroundInfluentialAntiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589 · cited 3×
“This is an open access article under improvement of response in metastatic disease with Taxol (Jain, 2014), whilst neoadjuvant studies showed contrasting results (Jain, 2014; Bear et al., 2012; Earl et al., 2015; Sikov et al., 2015; von Minckwitz et al., 2012).”
ResultScaltriti, M., Eichhorn, P. J., Cortés, J., Prudkin, L., Aura, C., Jiménez, J., Chandarlapaty, S., Serra, V., Prat, A., Ibrahim, Y. H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014835108 · Cited by 337 · cited 2×
“Cyclin E is associatedwith chromosome instability, is prognostic in breast cancer (Scaltriti et al., 2011), and lowmolecular weight isoforms increased angiogenesis in humanmelanoma cells in-vivo (Bales et al.”
BackgroundTolaney, S. M., Boucher, Y., Duda, D. G., Martin, J. D., Seano, G., Ancukiewicz, M., Barry, W. T., Goel, S., Lahdenrata, J., Isakoff, S. J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518808112 · Cited by 258 · cited 1×
“Whilst this work was submitted, a study was published (Tolaney et al., 2015)with similarwindowdesign, but a lower dose of bevacizumab.”
McIntyre, A., Patiar, S., Wigfield, S., Li, J.-L., Ledaki, I., Turley, H., Leek, R., Snell, C., Gatter, K., Sly, W. S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1877 · Cited by 239
Self-citationHegde, P. S., Jubb, A. M., Chen, D., Li, N. F., Meng, Y. G., Bernaards, C., Elliott, R., Scherer, S. J., & Chen, D. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2535 · Cited by 193 · cited 1×
“Circulating levels of short VEGFA isoforms, neuropilin-1 and VEGF receptor 1 expression in tumours or plasma, and VEGFA genetic variants have been reported as potential biomarkers of bevacizumab response (Lambrechts et al., 2013; Hegde et al., 2013).”
BackgroundSelf-citation
Cited by
Predicting cancer outcomes with radiomics and artificial intelligence in radiology
Bera, K., Braman, N., Gupta, A., Velcheti, V., & Madabhushi, A. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00560-7 · Cited by 819
HIFs, angiogenesis, and metabolism: Elusive enemies in breast cancer
de Heer, E. C., Jalving, M., & Harris, A. L. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137552 · Cited by 372
Self-citationJansen, R. W., van Amstel, P., Martens, R. M., Kooi, I. E., Wesseling, P., de Langen, A. J., Menke-Van der Houven van Oordt, C. W., Jansen, B. H. E., Moll, A. C., Dorsman, J. C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24893 · Cited by 63
Metadata
- Authors
- Mehta, S., Hughes, N. P., Li, S., Jubb, A., Adams, R., Lord, S., Koumakis, L., van Stiphout, R., Padhani, A., Makris, A., Buffa, F. M., & Harris, A. L.
- Venue
- eBioMedicine
- Publisher
- Elsevier BV
- Published
- 2016-08
- Volume
- 10
- Pages
- 109-116
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W2495002122
- Cited by
- 38
- References
- 7
- FWCI
- 1.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment. https://app.cochat.ai/papers/10.1016/j.ebiom.2016.07.017
- The paper
- Mehta, S., Hughes, N. P., Li, S., Jubb, A., Adams, R., Lord, S., Koumakis, L., van Stiphout, R., Padhani, A., Makris, A., Buffa, F. M., & Harris, A. L. (2016). Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment. eBioMedicine. https://doi.org/10.1016/j.ebiom.2016.07.017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.